Prognostički značaj zračenjem inducirane limfopenije kod bolesnika s rakom prostate visokog rizika by Katarina Antunac et al.
55
PROFESSIONAL PAPER Libri Oncol. 2018;46(2-3):55–59
 doi: 10.20471/LO.2018.46.02-03.09
PROGNOSTIC SIGNIFICANCE OF RADIATION INDUCED LYMPHOPENIA 
IN PATIENTS WITH HIGH RISK PROSTATE CANCER
KATARINA ANTUNAC1, PETAR SUTON1 and SARA BILIĆ-KNEŽEVIĆ2
1Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, 
Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 
2Department of Oncology and Nuclear Medicine, General Hospital Zadar, Zadar, Croatia
Summary
Lymphopenia is a known side-eff ect of radiotherapy but, being usually asymptomatic, its clinical value is just recently 
being recognized in the light of immunotherapy revival. Here we present clinical and laboratory data of 9 high-risk prostate 
patients that underwent whole pelvis radiotherapy combined with hormonal therapy. All patients experienced haemato-
logical toxicity during their treatment, with lymphopenia being the most profound. In addition, all of them were asymptom-
atic as regards to observed lymphopenia. After median follow up of 17 months 8/9 patients are still receiving hormonal 
treatment and have no evidence of their disease. The only patient with relapse discontinued hormonal therapy upon com-
pletion of radiotherapy. Therefore, we could not show any detrimental eff ect of observed lymphopenia on the outcome of 
these 9 patients.
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PROGNOSTIČKI ZNAČAJ ZRAČENJEM INDUCIRANE LIMFOPENIJE 
KOD BOLESNIKA S RAKOM PROSTATE VISOKOG RIZIKA
Sažetak:
Limfopenija je poznata nuspojava zračenja, međutim, kako je obično asimptomatska, njen klinički značaj je tek odne-
davno prepoznat s obzirom na rastući interes za imunoterapijom. Predstavljamo kliničke i laboratorijske podatke 9 bolesni-
ka s rakom prostate visokog rizika kod kojih je provedeno zračenje zdjelice u kombinaciji s hormonskom terapijom. Kod 
svih bolesnika je zabilježena hematološka toksičnost; limfopenija je bila najviše izražena. Sve opažene limfopenije su bile 
asimptomatske. Nakon medijana praćenja od 17 mjeseci 8 od 9 bolesnika je bez znakova bolesti te još primaju hormonsku 
terapiju. Jedini bolesnik s relapsom bolesti je prestao dobivati hormonsku terapiju po završetku zračenja. Sukladno navede-
nom, nismo uspjeli pokazati štetan učinak opažene limfopenije na ishod liječenja ovih 9 bolesnika.
KLJUČNE RIJEČI: rak prostate, zračenje zdjelice, limfopenija uzrokovana zračenjem
INTRODUCTION
Haematological toxici ty from post-prostatec-
tomy whole pelvis radiotherapy has been de-
scribed in literature. Lymphopenia has been ob-
served with standard fractionation (daily fractions 
of 1.8-2Gy) and neutropenia with hypofraction-
ation (daily fractions >2 Gy) (1). Lymphopenia is 
defi ned as a peripheral blood lymphocyte count 
<1.5x 109/L. Since lymphocytes account for about 
20-40% of overall white blood counts, it cannot be 
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detected without diff erential blood count. Lym-
phocytes are the most radiosensitive cells among 
erythroid, myeloid and lymphoid lineage (2). 
Lymphocytes staying within or circulating through 
a radiation portal are aff ected by radiotherapy; 
their lethal dose (LD) 50 is 2 Gy and LD90 3 Gy. 
Other haematological side eff ects such as throm-
bocytopenia, neutropenia or anemia are much 
more studied compared to lymphopenia given 
their clinically apparent and acute infl uence on 
patients, making them prone to bleeding, infec-
tions or fatigue. Eff ect of radiation on lymphocyte 
counts has been known for decades (3) but just re-
cently is its potential association with tumour con-
trol and patient outcomes being researched, bear-
ing in mind the role of immune system on tumour 
surveillance.
Aim of this analysis was to address severity 
and duration of haematological toxicity from 
whole pelvis radiotherapy in high- risk prostate 
cancer and its eff ect on tumour control. Whole 
pelvis radiotherapy is indicated in patients with 
high risk prostate cancer, when, according to no-
mogram, risk of metastases in pelvic lymph nodes 
exceeds 15%. Clinical target volume should in-
clude presacral lymph nodes, lymph nodes 
around iliac vessels and obturator lymph nodes 
(3). Usual prescribed dose, according to our insti-
tutional guidelines, is 46 Gy on pelvic lymph 
nodes (PTV1), 56 Gy on seminal vesicles (PTV2) 
and 74 Gy on prostate (PTV3), standard fraction-
ation. Irradiation starts with all 3 target volumes; 
therefore all patients receive irradiation of their 
pelvis during fi rst 5 weeks of treatment.
PATIENTS AND METHODS
We have monitored the counts of absolute 
white blood cells, lymphocytes, neutrophils, plate-
lets and heamoglobin in 9 patients with high risk 
prostate cancers undergoing whole pelvis radio-
therapy. All 9 patients were irradiated in 2016 and 
2017 at University Hospital for Tumours, Zagreb. 
Patients’ characteristics are shown in Table 1. Me-
dian patient age was 77 years (range 66-84), initial 
PSA values were between 7.15 and >100 ng/mL, 1 
patient had prostate adenocarcinoma Gleason 
score (GS) 3+3, Grade group (GG) 1, 3 patients GS 
3+4, GG 2, 2 patients GS 4+3, gg 3, 1 patient GS 3+5, 
GG 4, 1 patient GS4+4, GG 4, and 1 patient GS 4+5, 
GG 5. Median follow up (upon completion of ra-
diotherapy) was 17 months (range 9- 21 months).
All baseline blood counts values were within 
normal ranges. Prescribed dose on pelvic lymph 
nodes was 46Gy, on seminal vesicles 56 Gy and on 
prostate 74 Gy, 2 Gy per fraction, 5 days/week. Ra-
diation portals are shown on Figures 1 and 2. In all 
patients treatment started with whole pelvis irra-
diation. All patients received androgen depriva-
tion therapy; 3 patients received antiandrogen 
only (bicalutamide 150 mg) and 6 patients LHRH 
agonist with antiandrogen (fl utamide 3x 250 mg 





GS Hormonal therapy Follow up upon completion 
of radiotherapy
PSA level/outcome
77 11.95 4+5 LHRH agonist 21 months 0.01/NEDa
82 53.04 3+5 LHRH agonist 9 months 0.92/NED
84 29.53 4+3 Bicalutamide 150 mg 12 months 0.05/NED
66 38.22 4+3 LHRH agonist 9 months 0.01/NED
77 >100 3+4 Bicalutamide 150 mg 20 months 0.04/NED
76 52.73 3+4 Bicalutamide 150 mg 
(for 3 months, before 
and during RT)
17 months Biochemical relapse after 14 months (PSA 
3.73), bone and lymph node metastases 2 
months later (PSA 7.18) /AWDb
70 53.41 3+3 LHRH agonist 19 months 0.04/NED
72 31 3+4 LHRH agonist 15 months < 0.01/NED
82 7.15 4+4 LHRH agonist 21 month < 0.002/NED
a No evidence of disease
b Alive with disease
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therapy. Complete blood sample was obtained be-
fore the beginning of radiotherapy and then week-
ly during the treatment.
RESULTS
In all patients persistent decline of absolute 
white blood cells count (WBC) and haemoglobin 
level (Hb) was observed (WBC till 3.28x 109/L, Hb 
till 104 g/L) (Charts 1 and 2). No change in neutro-
phil and platelet counts was noticed. A signifi cant 
decline of lymphocyte count was observed in all 
patients, both in absolute values and percentage, 
with nadir values between 0.39 and 0.79x 109/L 
(median 0.54x 109/L) (Chart 3). Lymphopenias oc-
curred from 5th week of radiotherapy onwards, 
with doses ranging from 44 to 66 Gy (median be-
ing 52 Gy), hence 30 till 45 days from the begin-
ning of whole pelvis radiotherapy (median 36th 
day). By the end of radiotherapy lymphocyte 
counts gradually increased, but without reaching 
referral values (1.19- 3.35x 109/L). All observed 
lymphopenias were asymptomatic, both during 
and upon completion of radiation treatment.
After a median follow up of 17 months, 8 pa-
tients are without evidence of their disease and all 
of them are still receiving hormonal treatment: 
two patient bicalutamide and 6 patients LHRH 
Figure 1 and 2 Radiation portals
Chart 1 Lymphocyte counts (referent value range marked with blue)
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Chart 3 Haemoglobin value (g/L), (referent value range marked with blue)
Chart 2 WBC counts (referent value range marked with blue)
agonist. One patient had biochemical relapse after 
14 months and 2 months later positron emission 
tomography (PET) scan revealed bone and lymph 
node metastases. That patient discontinued hor-
monal treatment with bicalutamide after comple-
tion of radiotherapy.
DISCUSSION
Although well-known for decades, eff ect of 
radiation on lymphocyte counts has recently be-
come more and more interesting, following im-
munotherapy revival. Lower number of circulat-
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ing lymphocytes could be associated to lower 
 tumour lymphocyte infi ltration and weaker im-
munological anti- tumour response, all of which 
could translate into worse outcome.
According to literature data, association of 
treatment induced lymphopenias and worse out-
come was observed in patients with glioblastoma, 
head and neck squamous cancer, nasopharyngeal 
cancer, both non-small and small cell lung cancer, 
pancreatic cancer, oesophageal cancer and breast 
cancer (2).
As far as pelvic malignancies are concerned, 
two trials found association between lymphope-
nia and worse outcome, both in patients with cer-
vical cancer undergoing chemoradiotherapy. Wu 
et al. found threshold lymphocyte value of <0.5 
cells/mm3 2 months upon completion of the treat-
ment being associated with worse median overall 
survival: 21.2 vs 45.0 months, P = 0.03 (5). Cho and 
al. analysed 124 patients with FIGO stage I-III cer-
vical cancer who received weekly cisplatin-based 
concomitant chemoradiotherapy and brachyther-
apy. Patients with lymphopenia gr 2-3 had 5-year 
disease specifi c survival (DSS) and 3-year progres-
sion specifi c survival (PFS) signifi cantly higher 
compared to those with grade 4 lymphopenia (de-
fi ned as <200 cells/l): 84.8% vs. 50.4%, p<0.001, and 
80.7% vs. 50%, p=0.002, respectively (6).
Our patients did not receive concurrent che-
motherapy, which is known to also have an eff ect 
on lymphocyte counts. Since all of them experi-
enced lymphopenia, we could not make any clear 
conclusion on its eff ect on their outcome. The only 
patient that had disease recurrence discontinued 
hormonal treatment upon completion of radio-
therapy. Overall his hormonal therapy lasted for 3 
months, which is in contrast with recommended 
duration of two to three years for this subset of 
patients.
CONCLUSION
Clinically unapparent lymphopenia occurred 
in all 9 patients during radiotherapy, starting from 
30 to 45 days from the beginning of the treatment. 
After median follow up of 17 months 8/9 patients 
are without evidence of the disease. Although pa-
tient sample is quite small and follow up is short, 
it can still be concluded that lymphopenia did not 
have any eff ect on tumour control. One relapse 
should rather be att ributed to hormonal therapy 
discontinuation than to changes in immunological 
anti- tumour eff ect caused by radiation induced 
lymphopenia.
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